Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical dapsone gel for prevention and treatment of erlotinib-associated rash in NSCLC
2006-000390-30Phase 2Completed
- Sponsor
- Helsinki University Hospital
- Start
- Mar 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of dapsone in non-small cell lung cancer (NSCLC) and acneiform rash, sponsored by Helsinki University Hospital. Primary endpoint: Toxicity of dapsone topical gel. Started Mar 2006; status: completed.
02
Drugs
dapsone
03
Conditions
non-small cell lung cancer (NSCLC)acneiform rash
Beyond the preview
Go deeper on 2006-000390-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000390-30.